期刊文献+

HPV18E7抗原HLA-A2限制性CTL表位的初步筛选 被引量:8

Preliminary screening of HLA-A2-restricted CTL epitope derived from human papillomavirus 18E7 antigen
下载PDF
导出
摘要 目的:初步筛选人乳头瘤病毒18型E7抗原的HLA-A2限制性细胞毒性T淋巴细胞(CytotoxicTlymphocyte,CTL)表位,为表位免疫原性鉴定提供靶肽。方法:采用超基序、多项式和量化基序方案相结合的方法,对靶抗原HPV18E7的HLA-A2限制性细胞毒性T淋巴细胞表位进行预测,并应用固相合成法合成多肽,经RP-HPLC纯化及纯度分析,用质谱进行定性鉴定。结果:分别预测出5条、1条和6条九肽表位,综合三种预测方案确定其中1条为候选合成表位,合成肽的纯度大于95%,经质谱分析合成肽的分子量测定值与理论值相符。结论:超基序、多项式和量化基序方案联合应用提高预测效率,避免了在研究HPV18E7抗原表位时盲目合成多肽;所合成的多肽为高纯度靶肽,为后继的抗原表位的免疫原性的鉴定奠定了实验基础。 Objective:To screen the HLA-A2-restricted CTL epitopes of human papilloma virus 18 E7 antigen, and to identify the predicted HLA-A2-restricted CTL epitope candidate from HPV18E7 for immunogenicity identification. Methods:The CTL epitopes of HPV18E7 antigen were predicted by HLA-A2-binding peptide supermotif prediction method combined with the polynomial and quantitative motif method.The peptide was synthesized with solid phase strategies and identified with mass spectrometry, the purity of the peptide was detected by reverse-phase high performance liquid chromatography (RP-HPLC). Results: Five,one and six CIL epitopes were respectively predicted, among which one peptide was the candidate to be synthesized. The peptide was beyond 95% in purity and the measured value of molecular weight conformed to its theoretical value. Conclusions: The conbination of supermotif with the polynomial and quantitative motif method can improve the prediction efficiency and avoid synthesizing peptides aimlessly about HPV18E7 antigen. The synthesized peptide is the target peptide with high purity,the study provides basis for immunogenicity identification in future.
出处 《温州医学院学报》 CAS 2007年第2期100-103,共4页 Journal of Wenzhou Medical College
基金 国家自然科学基金资助项目(30500537)。
关键词 乳头瘤病毒 表位 淋巴细胞 E7抗原 固相合成 基序 papillomavirus epitope lymphocyte E7 antigen Solid phase synthesis, motif
  • 相关文献

参考文献13

  • 1Ferenczy A,Franco E.Persistent human papillomavirvus infection and cervical neoplasia[J].Lancet oncol,2002,3 (1):11-16.
  • 2Hebner CM,Laimins LA.Huamn papillomaviruses:basic mechanisms of pathogenesis and oncogenicity[J].Rev Med Virol,2006,16(2):83-97.
  • 3Munger K,Baldwin A,Edwards KM,et al.Mechanisms of human papillomavirus induced oncogenesis[J].J Vivol,2004,78(21):11451-11460.
  • 4Rotzschke O,Falk K,Stevanovic S,et al.Peptides motif of closely related HLA class Ⅰ molecules encompass substantial differences[J].Eur J Immunol,1992,22(9):2453-2456.
  • 5Sidney J,Grey HM,Kubo RT,et al.Practical,biochemical and evolutionary implications of HLA class Ⅰ supermotif[J].Immmunol Today,1996,17(6):261-266.
  • 6Gulukota K,Sidney J,Sette A,et al.Two complementary methods for predicting peptides binding major histocompatibility complex molecules[J].J Mol Biol,1997,267(5):1258-1267.
  • 7Parker KC,Bednarek MA,Coligan JI,et al.Scheme for ranking potential HLA-A2 binding peptides base on independent binding of indivdual peptide side-chains[J].J Immunol,1994,152(1):163-175.
  • 8Teruya K,Murphy AC,Burlin T,et al.Fmoc,based chemical synthesis and selective binding to supercoiled DNA of the P53 C-terminal segment and its phosphorylated and acetylated derivatives[J].J Pept Sci,2004,10(8):479-493.
  • 9Du C,Ramaley C,Mclean H,et al.High-performance liquid chromatography coupled with tandem masss pectrometry for the detection of amyloid Beta peptide related with Alzheimer's disease[J].J Biomol Tech,2005,16(4):356-363.
  • 10Clifford GM,Smith JS,Plummer M,et al.Human papillomavirus types in invasive cervical cancer worldwide:a meta-analysis[J].Br J cancer,2003,88(1):63-73.

二级参考文献6

共引文献3

同被引文献81

  • 1卢山珊,周韧,徐纪为.鼻腔及鼻窦内翻性乳头状瘤与人乳头状瘤病毒感染及病毒亚型的关系[J].中华耳鼻咽喉头颈外科杂志,2005,40(3):195-198. 被引量:22
  • 2Lindenbach BD,Rice CM.Unravelling hepatitis C virus rep-lication from genome to function[J].Nature,2005,436(7053):933-938.
  • 3Simmonds P,Holmes EC,Cha TA,et al.Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region[J].J Gen Virol,1993,74 (Pt 11):2391-2399.
  • 4Shepard CW,Finelli L,Alter MJ.Global epidemiology of hepatitis C virus infection[J].Lancet Infect Dis,2005,5(9):558-567.
  • 5Bowen DG,Walker CM.Adaptive immune responses in acute and chronic hepatitis C virus infection[J].Nature,2005,436(7053):946-952.
  • 6Wen JS,Duan ZL,Jiang LF.Identification of a Dengue vi-rus-specific HLA-A*0201-restricted CD8+T cell epitope[J].J Med Virol,2010,82(4):642-648.
  • 7Duenas-Carrera S.DNA vaccination against hepatitis C[J].Curr Opin Mol Ther,2004,6(2):146-150.
  • 8Houghton M,Abrignanl S.Prospects for a vaccine against the hepatitis C virus[J].Nature,2005,436(7053):961-966.
  • 9Lechner F,Jegerlehner A,Tissot AC,et al.Virus-like par-ticles as a modular system for novel vaccines[J].Intervirology,2002,45(4-6):212-217.
  • 10Shoukry NH,Grakoui A,Houghton M,et al.Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection[J].J Exp Med,2003,197(12):1645-1655.

引证文献8

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部